alrn-6924
Small moleculeexperimental
Clinical trial activity
6 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2014 (NCT02264613)
Timeline
2010s
- Jan 1, 2014
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Brain Neoplasms · Phase 1
- Breast Neoplasms · Phase 1
- Carcinoma, Non-Small-Cell Lung · Phase 1/Phase 2
- Drug Therapy · Phase 1
- Leukemia · Phase 1
- Leukemia, Myeloid, Acute · Phase 1
- Lymphoma · Phase 1/Phase 2
- Lymphoma, T-Cell, Peripheral · Phase 1/Phase 2
- Myelodysplastic Syndromes · Phase 1
- Neoplasms · Phase 1/Phase 2
- Small Cell Lung Carcinoma · Phase 1/Phase 2
- Tumor Suppressor Protein p53 · Phase 1
Mechanism of action
- E3 ubiquitin-protein ligase Mdm2INHIBITOR
MDM2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- alrn-6924
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05622058 | Phase 1 | Nov 30, 2022 | Aileron Therapeutics |
| NCT04022876 | Phase 1/Phase 2 (Phase 2) | Aug 31, 2019 | Aileron Therapeutics |
| NCT03725436 | Phase 1 | Jan 24, 2019 | National Cancer Institute (NCI), University of Texas at Houston |
| NCT03654716 | Phase 1 | Sep 30, 2018 | Harvard University |
| NCT02909972 | Phase 1 | Sep 1, 2016 | Aileron Therapeutics |
| NCT02264613 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2014 | Aileron Therapeutics |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Aileron Therapeutics | For profit | 4 | 4 | 2 | 2014 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2018 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2019 |
| University of Texas at Houston | Academic/Hospital | 1 | 1 | 1 | 2019 |
4 organizations
Page 1 / 1